Clinical Trial Update: Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

View source ↗

Summary

This clinical trial update describes a study evaluating fruquintinib plus albumin-bound paclitaxel with or without a PD-1 antibody as second-line treatment for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Fruquintinib (fruquintinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Gastric Cancer | Status: RECRUITING